Vericel (VCEL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$40.19-0.69%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VCEL
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 306.3 | 276.3 | 237.2 | 197.5 | 164.4 | 156.2 | 124.2 | 117.9 | 90.9 | 63.9 | 54.4 | 51.2 | 28.8 | 0.0 | 0.0 | 0.0 |
| Total Revenues | 306.3 | 276.3 | 237.2 | 197.5 | 164.4 | 156.2 | 124.2 | 117.9 | 90.9 | 63.9 | 54.4 | 51.2 | 28.8 | 0.0 | 0.0 | 0.0 |
| Cost of Revenues | 77.9 | 70.7 | 65.1 | 61.9 | 54.6 | 50.2 | 40.0 | 37.6 | 32.2 | — | — | — | — | — | — | — |
| Gross Profit | 228.4 | 205.6 | 172.1 | 135.6 | 109.8 | 106.0 | 84.2 | 80.3 | 58.7 | 33.6 | 26.1 | 24.7 | 11.5 | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 181.0 | 167.0 | 142.8 | 121.0 | 106.9 | 97.6 | 68.8 | 61.1 | 49.0 | 35.6 | 27.4 | 22.5 | 13.8 | 5.9 | 7.8 | 7.7 |
| R&D Expenses | 29.2 | 27.6 | 24.8 | 21.0 | 19.9 | 16.3 | 13.0 | 30.4 | 13.6 | 12.9 | 15.3 | 18.9 | 21.3 | 15.1 | 26.0 | 21.3 |
| Operating Income | 18.2 | 11.0 | 4.5 | (6.5) | (17.1) | (7.9) | 2.4 | (11.3) | (3.9) | (15.0) | (19.2) | (16.7) | (23.5) | (21.0) | (33.8) | (29.0) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 0.6 | 0.6 | 0.6 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest & Investment Income | 7.5 | 7.0 | 6.4 | 4.6 | 1.3 | 0.2 | 0.7 | 1.6 | 0.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 |
| Net Interest Expenses | — | — | — | (4.0) | (1.0) | (0.2) | (0.7) | (1.6) | (0.9) | 0.1 | 0.0 | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) |
| Other Non-Operating Income / Expenses | 6.8 | 6.3 | 6.0 | 4.1 | 1.1 | 0.3 | 0.7 | 1.6 | (4.2) | (2.3) | (0.3) | 0.3 | 3.6 | 5.3 | 4.3 | 9.4 |
| Asset Writedown | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | — | 17.4 | 10.5 | (2.4) | (16.0) | (7.6) | 2.9 | (9.7) | (8.1) | (17.3) | (19.6) | (16.3) | (19.9) | (15.6) | (29.5) | — |
| Income Tax Expense | — | 0.9 | 0.1 | 0.8 | 0.7 | (0.1) | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | 24.2 | 16.5 | 10.4 | (3.2) | (16.7) | (7.5) | 2.9 | (9.7) | (8.1) | (17.3) | (19.6) | (16.3) | (19.9) | (15.6) | (29.5) | (19.7) |
| Per Share | ||||||||||||||||
| Basic EPS | 0.47 | 0.33 | 0.21 | (0.07) | (0.35) | (0.16) | 0.06 | (0.22) | (0.20) | — | — | — | — | — | — | — |
| Diluted EPS | 0.46 | 0.32 | 0.20 | (0.07) | (0.35) | (0.16) | 0.06 | (0.22) | (0.20) | — | — | — | — | — | — | — |
| Revenue per Share | 5.86 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 51.1 | 50.3 | 48.8 | 47.6 | 47.1 | 46.5 | 45.2 | — | — | — | — | — | — | — | — | 38.6 |
| Diluted Weighted Avg Shares | 52.3 | 52.2 | 51.7 | 47.6 | 47.1 | 46.5 | 47.3 | — | — | — | — | — | — | — | — | 38.6 |
| Supplemental | ||||||||||||||||
| EBITDA | — | 22.6 | 10.0 | (1.8) | (13.1) | (4.9) | 4.8 | (9.6) | (2.5) | (13.4) | (17.4) | (15.1) | (22.8) | (20.5) | (33.1) | (28.4) |
| EBIT | 18.2 | 11.0 | 4.5 | (6.5) | (17.1) | (7.9) | 2.4 | (11.3) | (3.9) | (15.0) | (19.2) | (16.7) | (23.5) | (21.0) | (33.8) | (29.0) |
| Effective Tax Rate | — | — | — | -34.4% | -4.5% | 1.5% | 6.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.